Compare CVGW & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGW | PRME |
|---|---|---|
| Founded | 1924 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.9M | 536.4M |
| IPO Year | 2002 | 2022 |
| Metric | CVGW | PRME |
|---|---|---|
| Price | $26.09 | $3.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $33.50 | $7.56 |
| AVG Volume (30 Days) | 262.1K | ★ 2.8M |
| Earning Date | 06-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 1950.00 | 18.18 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $648,434,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | $652.25 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $18.40 | $1.40 |
| 52 Week High | $28.98 | $6.94 |
| Indicator | CVGW | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 44.55 |
| Support Level | $25.41 | $2.68 |
| Resistance Level | $26.86 | $3.72 |
| Average True Range (ATR) | 0.44 | 0.27 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 6.73 | 39.24 |
Calavo Growers Inc is engaged in the sourcing, packing, and distribution of fresh avocados, tomatoes, and papayas, and the processing of guacamole and other avocado products. The company delivers products to retail grocers, club and mass-merchandise stores, foodservice operators, and wholesalers, sourcing avocados from California, Mexico, and other key growing regions. Its operations include sorting, packing, ripening, and shipping fresh produce, and processing and packaging fresh and frozen guacamole. The company operates through two segments: Fresh, including avocados, tomatoes, papayas, and other fresh produce products, and Prepared, including guacamole and avocado pulp, with the majority of revenue generated from the Fresh segment and geographically from the United States.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.